Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
BNAI has added new corporate events since the January squeeze — a pending Cataneo acquisition, an Accelevate investment, Q1 liquidity improvements and continued international AI expansion. The story is more developed, but the stock remains speculative, thin, headline-sensitive and vulnerable to violent swings.
All-cash deal at $124 per share — 40% premium to prior close. GSK’s largest oncology acquisition in over a decade. Two NDAs under FDA review, one PDUFA in September 202
The first patient randomized in PREDICT-1 does not erase the DIAMOND disappointment, but it gives Oculis a fresh late-stage catalyst path. The equity story is now less about OCS-01 in DME and more about whether Licaminlimab and Privosegtor can rebuild confidence from a funded pipeline reset.
A full deep dive into the June 2026 vopimetostat + daraxonrasib readout, the PRMT5/RAS(ON) combination thesis, the role of Revolution Medicines, Tango's cash runway, pipeline optionality, ownership structure, key catalysts and the risks behind one of the strongest biotech moves of the year.
BCDA BioCardia deep dive — CardiAMP cell therapy, FDA PMA path confirmed June 2026, Japan PMDA Q4 2026. Educational content only.
A full trader-focused deep dive on Nurix Therapeutics, the Roche collaboration for bexobrutideg, the company’s targeted protein degradation platform, its clinical and partnered pipeline, financial runway, ownership profile, catalysts, risks and the scenarios that matter after the June 8 announcement.
The June 11, 2026 catalyst is days away: oral presentation at EHA in Stockholm, updated Phase 1 data on ELVN-001 in chronic myeloid leukemia, and the pivotal Phase 3 ENABLE-2 trial launch expected in H2 2026. Cash of $452M, no near-term financing pressure, a new CEO with commercial ambitions.
A deep-dive report on Senseonics after fresh ADA 2026 real-world evidence for Eversense 365, the first and only one-year implantable continuous glucose monitoring system, with new open-loop and closed-loop data, twiist AID integration, commercial momentum, European expansion, financing risk and the next execution test.
After a nine-week winning streak, the S&P 500 finally broke lower as strong labor data pushed yields higher and forced traders to reprice the “easy money plus AI growth” narrative. Next week, inflation data, Treasury auctions and major software earnings will decide whether this was only a reset — or the beginning of a deeper rotation.
Three biotechnology and healthcare names are standing out this morning for very different reasons. Zenas BioPharma (Nasdaq: $ZBIO) is the highest-quality fundamental setup among the group because the latest news is tied to a registrational Phase 3 dataset, a peer-reviewed medical publication, a major rheumatology conference and a recently submitted Biologics License Application. Verastem Oncology (Nasdaq: $VSTM) offers the cleanest oncology headline because the company has expanded the regulatory visibility of its KRAS G12D program through an FDA Fast Track designation in non-small cell lung cancer. Edesa Biotech (Nasdaq: $EDSA) is the most speculative of the three, but it has a timely conference catalyst in acute kidney injury, an area with high mortality, limited pharmacological options and a plausible inflammatory biology angle.
After OCS-01 failed to meet the primary visual acuity endpoint in both DIAMOND Phase 3 trials for diabetic macular edema, Oculis is no longer a clean near-term DME filing story. The new setup is a cash-rich ophthalmology and neuro-ophthalmology pipeline reset, with Privosegtor and Licaminlimab now carrying the next real tests.
Primary endp
Fulcrum was previously framed on Merlintrader as a cleaner but harsher one-asset biotech setup: pociredir had shown real fetal hemoglobin movement, but the next value bridge depended on FDA alignment, trial design and long-term safety confidence. The June 2026 update did not merely delay that bridge. It broke it.
A single-stock deep dive on the Phase 2b PLATEAU trial, Wegovy supply, enobosarm’s GLP-1 adjunct thesis, FDA pathway, cash runway, dilution risk, catalysts, and the real bull-bear setup behind Veru.
A focused regulatory calendar screen for June, excluding major pharmaceutical companies and highlighting the smaller names where an FDA decision may still matter for valuation, narrative, liquidity, and trading behavior.
A deep dive into tebipenem HBr, the GSK partnership, the PIVOT-PO data package, Spero’s financial position, and the key regulatory risks heading into the June 18, 2026 PDUFA date.
Cardiff Oncology, BeyondSpring and Lantern Pharma each used the final day of ASCO 2026 to push a different small-cap oncology story: a randomized colorectal cancer signal moving toward a registrational program, a post-checkpoint lung cancer combination with long follow-up, and a biomarker-focused NSCLC dataset tied to an FDA-cleared protocol amendment.
Apogee Therapeutics (NASDAQ: APGE) is a clinical-stage biopharmaceutical company developing a pipeline of next-generation, extended half-life (HLE) antibodies engineered to treat immunological and inflammatory diseases — with atopic dermatitis (AD) and asthma as its primary targets. The company's thesis is direct and compelling: take validated biological targets, engineer antibodies with dramatically longer half-lives, and deliver comparable or superior efficacy with a fraction of the injections required by existing therapies.
After Nvidia CEO Jensen Huang pushed Marvell into the center of the AI conversation, $MRVL has become one of the most watched semiconductor stocks in the market. The real story is not only the headline. It is custom silicon, high-speed switching, optical connectivity, data-center power limits, and whether Marvell can grow into a valuation that now prices in a much larger future.
Nasdaq: $LASE Defense Technology Published June 3, 2026 Laser Photonics Corporation (Nasdaq: $LASE): Anti-Drone Laser Deep Dive After MEIA Vulcan Selection Laser Photonics has moved back into the speculative small-cap spotlight after its Laser Shield Anti-Drone system was selected under…
UroGen and Teva resolved the patent litigation around JELMYTO. The headline is legal, but the real investor story is broader: UroGen gets a clearer commercial window while ZUSDURI scales, and Teva secures future generic optionality while its larger turnaround story continues to shift toward innovative medicines, biosimilars and disciplined execution.